---
layout: default
title: Acitretin
description: "Acitretin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 4 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 13
evidence_level: L3
indication_count: 4
---

# Acitretin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>4</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Acitretinï¼šå¾ä¹¾ç™¬åˆ°é’æ˜¥ç—˜æ–°é©æ‡‰ç—‡æ¢ç´¢

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Acitretin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Acitretin åŸæœ¬ç”¨æ–¼åš´é‡æ€§ä¹¾ç™¬åŠçš®è†šè§’åŒ–ç—‡ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**é’æ˜¥ç—˜ (acne)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **1 å€‹è‡¨åºŠè©¦é©—**å’Œ **18 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | åš´é‡æ€§ç‰›çš®ç™¬ã€çš®è†šè§’åŒ–ç—‡ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | acne (disease)ã€pediatric systemic lupus erythematosusã€fetal erythroblastosisã€familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.94% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 6 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. acne (disease)</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.94%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Acitretin å±¬æ–¼ç¬¬äºŒä»£èŠ³é¦™æ—ç¶­ç”Ÿç´  A é…¸è¡ç”Ÿç‰©ï¼ˆretinoidï¼‰ï¼Œå…¶ä¸»è¦ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š
1. èª¿ç¯€è§’è³ªç´°èƒåˆ†åŒ–èˆ‡å¢æ®–
2. æŠ‘åˆ¶çš®è„‚è…ºæ´»æ€§
3. æŠ—ç™¼ç‚ä½œç”¨
4. å…ç–«èª¿ç¯€åŠŸèƒ½

é’æ˜¥ç—˜çš„ç—…ç†æ©Ÿè½‰æ¶‰åŠçš®è„‚è…ºéåº¦åˆ†æ³Œã€æ¯›å›Šè§’åŒ–ç•°å¸¸ã€ç—¤ç˜¡æ¡¿èŒå¢æ®–åŠç™¼ç‚åæ‡‰ã€‚Retinoids é¡è—¥ç‰©ï¼ˆå¦‚ isotretinoinï¼‰å·²æ˜¯åš´é‡é’æ˜¥ç—˜çš„æ¨™æº–æ²»ç™‚ã€‚

Acitretin èˆ‡ isotretinoin åŒå±¬ retinoidsï¼Œä½† acitretin å‚³çµ±ä¸Šè¼ƒå°‘ç”¨æ–¼é’æ˜¥ç—˜ï¼Œä¸»è¦å› ç‚ºå…¶æŠ‘åˆ¶çš®è„‚è…ºçš„æ•ˆæœè¼ƒ isotretinoin å¼±ã€‚ç„¶è€Œï¼Œæ–‡ç»é¡¯ç¤º acitretin åœ¨ä»¥ä¸‹æƒ…æ³å¯ä½œç‚ºæ›¿ä»£é¸æ“‡ï¼š
- Isotretinoin æ²»ç™‚å¤±æ•—å¾Œçš„ç¶­æŒç™‚æ³•
- åŒ–è†¿æ€§æ±—è…ºç‚ï¼ˆhidradenitis suppurativa / acne inversaï¼‰åˆä½µçµç¯€å›Šè…«å‹é’æ˜¥ç—˜

2002 å¹´å€‹æ¡ˆå ±å‘Š (PMID: 12080949) é¡¯ç¤ºï¼Œisotretinoin æ²»ç™‚ç„¡æ•ˆçš„çµç¯€å›Šè…«å‹é’æ˜¥ç—˜æ‚£è€…ï¼Œä½¿ç”¨ acitretin å¾Œç²å¾—é¡¯è‘—æ”¹å–„ã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT04663906](https://clinicaltrials.gov/study/NCT04663906) | N/A | UNKNOWN | 300 | ç ”ç©¶å£æœ isotretinoinï¼ˆåŒå±¬ retinoidï¼‰åœ¨ COVID-19 æ„ŸæŸ“é¢¨éšªçš„å½±éŸ¿ |

*è¨»ï¼šç›®å‰ç„¡å°ˆé–€é‡å° acitretin æ²»ç™‚é’æ˜¥ç—˜çš„è¨»å†Šè‡¨åºŠè©¦é©—*

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [12080949](https://pubmed.ncbi.nlm.nih.gov/12080949/) | 2002 | Case Report | Cutis | Isotretinoin ç„¡æ•ˆçš„çµç¯€å›Šè…«å‹é’æ˜¥ç—˜åˆä½µåŒ–è†¿æ€§æ±—è…ºç‚ï¼Œacitretin ç¶­æŒæ²»ç™‚æˆåŠŸ |
| [25640693](https://pubmed.ncbi.nlm.nih.gov/25640693/) | 2015 | Guideline | JEADV | æ­æ´²åŒ–è†¿æ€§æ±—è…ºç‚æ²»ç™‚æŒ‡å¼•ï¼ŒæåŠ acitretin ç‚ºæ²»ç™‚é¸é … |
| [29234829](https://pubmed.ncbi.nlm.nih.gov/29234829/) | 2018 | Review | Der Hautarzt | åŒ–è†¿æ€§æ±—è…ºç‚è—¥ç‰©æ²»ç™‚ï¼šisotretinoin ç™‚æ•ˆæœ‰é™ï¼Œacitretin æ•ˆæœè¼ƒä½³ |
| [20874789](https://pubmed.ncbi.nlm.nih.gov/20874789/) | 2011 | Journal Article | Br J Dermatol | 25 å¹´ acitretin æ²»ç™‚åŒ–è†¿æ€§æ±—è…ºç‚é•·æœŸè¿½è¹¤ï¼Œç™‚æ•ˆè‰¯å¥½ |
| [8573927](https://pubmed.ncbi.nlm.nih.gov/8573927/) | 1995 | Review | Dermatology | Retinoids èˆ‡çš®è„‚è…ºæ´»æ€§ï¼šæ¯”è¼ƒä¸åŒ retinoids çš„æŠ—ç—˜æ•ˆæœ |
| [9074840](https://pubmed.ncbi.nlm.nih.gov/9074840/) | 1997 | Review | Drugs | Retinoids åœ¨çš®è†šç§‘çš„ç¾æ³èˆ‡æœªä¾†ï¼šåŒ…å«ç—¤ç˜¡ç›¸é—œæ‡‰ç”¨ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. pediatric systemic lupus erythematosus</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.35%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.35%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. fetal erythroblastosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.28%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.28%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.10%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.10%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬022117è™Ÿ | æ–°å®šåº·ç™¬è† å›Š 25mg | è† å›ŠåŠ‘ | åš´é‡æ€§ç‰›çš®ç™¬ã€çš®è†šè§’åŒ–ç—‡ |
| è¡›ç½²è—¥è¼¸å­—ç¬¬022118è™Ÿ | æ–°å®šåº·ç™¬è† å›Š 10mg | è† å›ŠåŠ‘ | åš´é‡æ€§ç‰›çš®ç™¬ã€çš®è†šè§’åŒ–ç—‡ |

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è—¥ç‰©äº¤äº’ä½œç”¨

**Major äº¤äº’ä½œç”¨ï¼š**
- Tetracyclinesï¼ˆDoxycyclineã€Minocyclineã€Tetracyclineï¼‰ï¼šå¢åŠ å‡æ€§è…¦ç˜¤é¢¨éšª
- Vitamin Aï¼šå¢åŠ ç¶­ç”Ÿç´  A éå¤šç—‡é¢¨éšª
- Ethanolï¼ˆé…’ç²¾ï¼‰ï¼šå¯èƒ½å°‡ acitretin è½‰æ›ç‚º etretinateï¼Œå»¶é•·åŠè¡°æœŸè‡³æ•¸æœˆ
- Isotretinoinï¼šç¦æ­¢ä½µç”¨ï¼Œå¢åŠ ç¶­ç”Ÿç´  A æ¯’æ€§
- Methotrexateï¼šå¢åŠ è‚æ¯’æ€§é¢¨éšª
- å£æœé¿å­•è—¥ï¼ˆLevonorgestrelã€Norethisterone ç­‰ï¼‰ï¼šå¯èƒ½é™ä½é¿å­•æ•ˆæœ

**Moderate äº¤äº’ä½œç”¨ï¼š**
- ç£ºèƒºå°¿ç´ é¡é™è¡€ç³–è—¥ï¼ˆGlimepirideã€Glipizide ç­‰ï¼‰ï¼šå¯èƒ½å½±éŸ¿è¡€ç³–æ§åˆ¶
- å…‰æ•æ„Ÿè—¥ç‰©ï¼ˆAminolevulinic acidã€Methoxsalen ç­‰ï¼‰ï¼šå¢åŠ å…‰æ•æ„Ÿåæ‡‰

### é‡è¦è­¦èª
- **çµ•å°ç¦æ­¢æ‡·å­•**ï¼šacitretin å…·æœ‰å¼·çƒˆè‡´ç•¸æ€§ï¼Œè‚²é½¡å©¦å¥³å¿…é ˆæ–¼æ²»ç™‚å‰ã€ä¸­ã€å¾Œä½¿ç”¨æœ‰æ•ˆé¿å­•æªæ–½
- å› å¯èƒ½è½‰æ›ç‚º etretinateï¼Œ**åœè—¥å¾Œéœ€é¿å­•è‡³å°‘ 3 å¹´**
- **ç¦æ­¢é£²é…’**ï¼šé…’ç²¾æœƒä¿ƒé€² acitretin è½‰æ›ç‚ºé•·æ•ˆ etretinate
- å®šæœŸç›£æ¸¬è‚åŠŸèƒ½åŠè¡€è„‚

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šEthanol consumption with acitretin leads to the formation of etretinate, which has a much longer half-life than acitretin.  Major human fetal abnormalities have been associated with the administration...
- å»ºè­°ï¼šFemale patients should be warned that ethanol is contraindicated during active treatment with acitretin and for two months after cessation of therapy.



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Alcoholism** ğŸŸ¡ Moderate
- Like other retinoids, acitretin is a teratogen.  The concurrent use of alcohol and acitretin has been associated with the formation of etretinate, a related retinoid drug with a considerably longer half-life (mean: 120 days vs. 49 hours).  Alcohol sh...

**ç³–å°¿ç—… (Diabetes Mellitus)** ğŸŸ¡ Moderate
- The use of acitretin may adversely affect blood sugar levels and result in problems with blood sugar control.  In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.  It is recommended to moni...

**Toxic Optic Neuropathy** ğŸŸ¡ Moderate
- Ophthalmologic manifestations have been reported with the use of acitretin.  It is recommended that any patient treated with acitretin who is experiencing visual difficulties should discontinue the drug and undergo ophthalmologic evaluation.

**Hyperlipidemias** ğŸŸ¢ Minor
- Acitretin is contraindicated in patients with chronic abnormally elevated blood lipid values.  It is recommended to evaluate lipid status in patients before initiation of therapy and periodically until the lipid response to the drug is established.  ...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¢ Minor
- The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with acitretin is contraindicated in patients with severely impaired liver function.

*å¦æœ‰ 3 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Acitretin èˆ‡ isotretinoin åŒå±¬ retinoidsï¼Œå…·æœ‰ç›¸ä¼¼çš„æŠ—è§’åŒ–åŠæŠ—ç™¼ç‚æ©Ÿè½‰ã€‚æ–‡ç»é¡¯ç¤ºå…¶åœ¨ isotretinoin æ²»ç™‚å¤±æ•—æˆ–éœ€é•·æœŸç¶­æŒæ²»ç™‚çš„é’æ˜¥ç—˜æ‚£è€…ä¸­æœ‰æ‡‰ç”¨åƒ¹å€¼ã€‚ç‰¹åˆ¥æ˜¯åœ¨åŒ–è†¿æ€§æ±—è…ºç‚åˆä½µé’æ˜¥ç—˜çš„æƒ…æ³ä¸‹ï¼Œacitretin å¯èƒ½æ¯” isotretinoin æ›´æœ‰æ•ˆã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ’é™¤æ‡·å­•å¯èƒ½æ€§ï¼Œè‚²é½¡å©¦å¥³éœ€ä½¿ç”¨å…©ç¨®æœ‰æ•ˆé¿å­•æ–¹æ³•
- å®Œå…¨ç¦æ­¢é£²é…’
- å®šæœŸç›£æ¸¬è‚åŠŸèƒ½ï¼ˆALTã€ASTï¼‰åŠè¡€è„‚ï¼ˆTGã€Cholesterolï¼‰
- é¿å…ä½µç”¨ç¶­ç”Ÿç´  A è£œå……åŠ‘
- é¿å…ä½µç”¨å››ç’°é»´ç´ é¡æŠ—ç”Ÿç´ 
- è¨­è¨ˆ RCT æ¯”è¼ƒ acitretin èˆ‡ isotretinoin åœ¨ä¸åŒé¡å‹é’æ˜¥ç—˜çš„ç™‚æ•ˆ


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Vinorelbine]({{ "/drugs/vinorelbine/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Lornoxicam]({{ "/drugs/lornoxicam/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Amcinonide]({{ "/drugs/amcinonide/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Human Immunoglobulin G]({{ "/drugs/human_immunoglobulin_g/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Acitretinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/acitretin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_acitretin,
  title = {Acitretinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/acitretin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
